Inloggen

Login
 
Wachtwoord vergeten?

Aandeel Kiadis Pharma AEX:KDS, NL0011323407

  • 1,690 29 sep 2020 16:05
  • +0,010 (+0,60%) Dagrange 1,650 - 1,720
  • 264.902 Gem. (3M) 648,5K

Maart 2019

Volgen
 
Klik hier om dit forumtopic te volgen en automatisch op de hoogte gehouden te worden bij nieuwe berichten.
622 Posts
Pagina: 1 2 3 4 5 6 ... 32 »» | Laatste | Omlaag ↓
  1. forum rang 6 C200 1 maart 2019 07:37
    Kiadis Pharma to present at upcoming investor conferences in

    March 2019

     

     

    Amsterdam, The Netherlands, March 1, 2019 - Kiadis Pharma N.V. ("Kiadis Pharma" or the "Company") (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company, today announces that it is scheduled to present at the following investor conferences in March 2019.

     

    Cowen Healthcare Conference

    March 11-13, 2019, Marriott Copley Place, Boston, MA, USA

    Kiadis will be presenting on March 12th at 10:00 EST.

     

    BioCapital Europe

    March 14, 2019, Sofitel Legend Amsterdam The Grand, Amsterdam, Netherlands

    Kiadis will be presenting at 17:00 CET.

     

    Oppenheimer 29th Annual Healthcare Conference

    March 19-20, 2019, The Westin New York Grand Central, New York, NY, USA

    Kiadis will be presenting on March 19, 2019 at 14:45 EST.

     

    KBC Securities Healthcare Conference

    March 27, 2019, Convene Grand Central, New York, NY, USA

    Kiadis will be participating and hosting meetings with investors; there are no company presentations at this conference.

     

    Kiadis Contacts:

     

    Kiadis Pharma:

    Amy Sullivan, SVP, Corporate Affairs

    Tel. +1 508 479 3480

    a.sullivan@kiadis.com

    Optimum Strategic Communications:

    Mary Clark, Supriya Mathur, Hollie Vile

    Tel: +44 203 950 9144

    David Brilleslijper (Amsterdam)

    Tel: +31 610 942 514

    kiadis@optimumcomms.com

  2. forum rang 6 Endless 1 maart 2019 08:18
    quote:

    C200 schreef op 1 maart 2019 07:37:


    Kiadis Pharma to present at upcoming investor conferences in

    March 2019

     

     

    Amsterdam, The Netherlands, March 1, 2019 - Kiadis Pharma N.V. ("Kiadis Pharma" or the "Company") (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company, today announces that it is scheduled to present at the following investor conferences in March 2019.

     

    Cowen Healthcare Conference

    March 11-13, 2019, Marriott Copley Place, Boston, MA, USA

    Kiadis will be presenting on March 12th at 10:00 EST.

     

    BioCapital Europe

    March 14, 2019, Sofitel Legend Amsterdam The Grand, Amsterdam, Netherlands

    Kiadis will be presenting at 17:00 CET.

     

    Oppenheimer 29th Annual Healthcare Conference

    March 19-20, 2019, The Westin New York Grand Central, New York, NY, USA

    Kiadis will be presenting on March 19, 2019 at 14:45 EST.

     

    KBC Securities Healthcare Conference

    March 27, 2019, Convene Grand Central, New York, NY, USA

    Kiadis will be participating and hosting meetings with investors; there are no company presentations at this conference.

     

    Kiadis Contacts:

     

    Kiadis Pharma:

    Amy Sullivan, SVP, Corporate Affairs

    Tel. +1 508 479 3480

    a.sullivan@kiadis.com

    Optimum Strategic Communications:

    Mary Clark, Supriya Mathur, Hollie Vile

    Tel: +44 203 950 9144

    David Brilleslijper (Amsterdam)

    Tel: +31 610 942 514

    kiadis@optimumcomms.com




    Lijkt me toch dat ze echt op positief advies inspelen. Weliswaar communiceert Kiadis niet goed over de voortgang v an beantwoorden van de vragen maar in hun acties geven ze wel duidelijk weer dat het goed zit.
  3. forum rang 5 Sparrow2 1 maart 2019 14:59
    Wellicht zal dit ooit wel gepubliceerd zijn hier op het forum. Toch nog eventjes erbij zetten.

    CHMP Agenda update 31 januari 2019

    Kiadis Pharma Netherlands B.V.; adjunctive treatment in haematopoietic stem cell transplantation (HSCT) for a malignant disease

    Scope: Request by the applicant for an extension to the clock stop to respond to the List of Outstanding Issues adopted on 20.09.2018

    Action: For adoption

    List of Outstanding Issues adopted on 20.09.2018, 25.05.2018. List of Questions adopted on 08.09.2017.

    www.ema.europa.eu/en/documents/agenda...
622 Posts
Pagina: 1 2 3 4 5 6 ... 32 »» | Laatste |Omhoog ↑

Plaats een reactie

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord

Direct naar Forum

Kiadis Pharma Meer »

Koers 1,690   Verschil +0,01 (+0,60%)
Laag 1,650   Volume 264.902
Hoog 1,720   Gem. Volume 648.498
29 sep 2020 16:05
label premium

Grote verrassing bij Kiadis

Het laatste advies leest u als IEX Premium-lid

Inloggen Ontdek Premium
 
Quotedata: Amsterdam realtime by Euronext, other realtime by Cboe Europe Ltd.   US stocks: by NYSE & Cboe BZX Exchange, 15min delayed
#/^ Index indications calculated real time, zie disclaimer, streaming powered by VWD Group Crypto data by Crypto Compare